13,923 Shares in Bristol Myers Squibb Company $BMY Bought by USA Financial Formulas

USA Financial Formulas purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, Holdings Channel reports. The fund purchased 13,923 shares of the biopharmaceutical company’s stock, valued at approximately $919,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Primecap Management Co. CA acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $1,436,115,000. Legal & General Group Plc bought a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $980,862,000. BlackRock Inc. increased its position in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp increased its position in Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the period. Finally, SG Americas Securities LLC increased its position in Bristol Myers Squibb by 153.8% in the 1st quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company’s stock valued at $540,393,000 after acquiring an additional 5,399,407 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Wall Street Analysts Forecast Growth

BMY has been the subject of several analyst reports. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. Leerink Partners cut shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $73.00 to $59.00 in a research note on Monday, October 5th. Piper Sandler restated an “overweight” rating and issued a $82.00 price objective (up from $75.00) on shares of Bristol Myers Squibb in a report on Wednesday, September 16th. Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $76.00 target price on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $64.88.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $59.69 on Friday. The stock’s 50 day moving average is $63.55 and its 200 day moving average is $60.29. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a market cap of $121.94 billion, a P/E ratio of 13.15, a P/E/G ratio of 0.30 and a beta of 0.19. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.56 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.